DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market with Focus on The Premium Eyewear (2018-2022 Edition)” report has been added to ResearchAndMarkets.com’s offering. The global eyewear market has increased with a healthy growth rate over the years and…
Category: Business
More than 180 Children’s Hospital Los Angeles Physicians Named “Top Doctors” in Annual List Honoring the Region’s Most Esteemed Specialists
LOS ANGELES–(BUSINESS WIRE)–More than 180 Children’s Hospital Los Angeles physicians were named Top Doctors by Pasadena Magazine, honoring the region’s most esteemed specialists.
In Australia, NovaTears® Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On
HEIDELBERG, Germany–(BUSINESS WIRE)–#AFT–Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTe…
The $65.25Bn Global Ophthalmic Devices Market to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Devices Market – Forecasts from 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic device market is projected to grow at a CAGR of 5.01% to reach US$65.248 billion in 2023 f…
Uveitis – Epidemiology Forecast to 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Uveitis – Epidemiology Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. Uveitis – Epidemiology Forecast, 2025 provides an overview of the epidemiology trends of Uveitis in seven major markets (…
Global Eyewear Market by Product Type, Lens Material, End User, Distribution Channel and Geography – Forecast to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market – Segmented by Product Type, Lens Material, End User, Distribution Channel and Geography – Growth, Trends and Forecasts (2018 – 2023)” report has been added to ResearchAndMarkets.com’s offering. The g…
Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform. The trial is a multi-center, randomized, masked evaluation of nepafenac vs. placebo in 75 patients undergoing cataract surgery. The primary endpoint is to evaluate pain and the secondary endpoint is to evalua
Second Sight Appoints Pat Ryan Chief Operating Officer
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Ma
2020 On-site appoints Alexis McLaughlin as Chief Executive Officer, Closes Over $5MM in Series B Financing and Named to the Inc. 5000
BOSTON–(BUSINESS WIRE)–#HR–2020 On-site (2020), America’s leading provider of on-site vision care for businesses and schools, serving over 450 leading employers, announced this morning the appointment of Alexis McLaughlin as 2020’s new Chief Executive Officer. McLaughlin will also join 2020’s Board of Directors. Most recently, McLaughlin was SVP/General Manager of Retail Licensed Brands at Luxottica Retail, where she was responsible for $500MM in revenue across 1,000 stores in North America. In h
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and EudraCT 2017-002763-18) enrolled 83 patients at 13 sites across the United States, Germany and Italy. Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet ne
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences has boosted its finance team with two key appointments, Chief Financial Officer Julie Feder and VP of Finance Kylie Reynolds.
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global l…
PolyActiva Commences Its First Phase I Clinical Trial with Potential to Improve Daily Lives of Millions of Glaucoma Patients
MELBOURNE, Australia–(BUSINESS WIRE)–Revolutionary new glaucoma treatment, which could remove need for eye drop use, enters clinical trials with USD$12m venture capital-backing.
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced t…
Global Optical Coherence Tomography for Ophthalmology Market 2018-2022| Conventional OCT Systems Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#MedicalImaging–Technavio market research analysts expect the global optical coherence tomography for ophthalmology market to grow at a CAGR of almost 7% until 2022.
Patient-Driven Gene Therapy Company ReflectionBio Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD)
HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio’s RBIO-101 program (AAV.CYP4V2), an AAV-based gene therapy product for treating Bietti’s Crystalline Dystrophy (BCD). “Receiving orphan drug designation from the FDA is a miles
$3 Billion Retinal Surgery Devices Market – Global Forecast to 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Surgery Devices Market (By Devices Segment, Application, Geography, Region and Company Profile) – Global Forecast to 2025” company profile has been added to ResearchAndMarkets.com’s offering. The global retinal sur…
EyeSouth Expands into South Florida Through Affiliation with Florida Eye Microsurgical Institute
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed a strategic partnership with Florida Eye Microsurgical Institute and Boynton Beach ASC (“Florida Eye Microsurgical”), expanding its presence into the South Florida region. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower middle market healthcare private equity firm. Florida Eye Microsurgical is led by ophthalmolog
The $3.91Bn Global Market for Eye Testing Equipment to 2025: Analysis by Device, Application, End-User and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eye Testing Equipment Market by Device, Application, and End User – Global Opportunity Analysis and Industry Forecast, 2017-2025” report has been added to ResearchAndMarkets.com’s offering. The global eye testing equipment…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…